FDA Approved: PROMACTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for PROMACTA (eltrombopag olamine) to update its labeling; this action may include changes to indications and dosing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Immune Thrombocytopenia

Drugs mentioned

• Promacta (eltrombopag)

Snippet

SUPPL AP for PROMACTA (ELTROMBOPAG OLAMINE)